CJC-1295

Also known as: CJC-1295 DAC, Modified GRF 1-29

GH/GHRH Research Compound

Growth hormone-releasing hormone analog

Mechanism of Action

Stimulates growth hormone release from the pituitary. Often combined with a GHRP for synergistic effects.

66.7% of observational mentions of CJC-1295 (n=78) reference concurrent use with Ipamorelin, making it one of the most stack-dependent peptides in available data. A GHRH analog (also known as CJC-1295 DAC or Modified GRF 1-29), it has no FDA approval for human use. Self-reported outcomes most frequently center on body composition (36.4%), sleep quality (21.8%), and growth hormone effects (20.0%).

402

Community Posts

169

Users Discussing

3

Research Articles

1

Clinical Trials

Reported Outcomes

Clinical grade reflects published research; Community grade reflects user reports (n=402).

Outcome

Clinical

Community

Reported by

Body Composition

Changes in muscle vs fat ratio

Clinical: D

Community: A

30% (65)

Sleep Quality

Effects on sleep quality

Clinical: D

Community: B

30% (83)

Growth Hormone

Effects on growth hormone levels

Clinical: C

Community: A

28% (77)

The provided abstracts classify CJC-1295 as a growth hormone-releasing hormone (GHRH) targeted in anti-doping protocols. The texts focus on analytical detection methods (LC-HRMS/MS) and pharmacokinetics (detection windows) in plasma rather than measuring physiological changes in growth hormone levels.

Energy Levels

Changes in energy and fatigue levels

Clinical: D

Community: B

16% (33)

Mental/Mood

Effects on mood and cognitive function

Clinical: D

Community: A

12% (25)

Muscle Repair

Muscle recovery and repair from exercise or injury

Clinical: D

Community: B

3% (6)

Who Discusses CJC-1295

From community reports with demographic data.

Gender

Male 86%

Female 14%

n=72

Age Distribution

45

median age

range: 26-64

<30

30s

40s

50s

60+

n=33

Side Effects

Limited data

Based on 8 user reports (n=8). Frequency indicates how often each was mentioned.

Uncommon (1-5%)

Post Injection Pain (Pip)

Mild 1 reports 5.9%

Bump And Redness At Injection Site

Mild 1 reports 5.9%

Messed Up Circadian Rhythms (Sleepiness

Mild 1 reports 5.9%

Tiredness

Mild 1 reports 5.9%

Difficult To Wake Up)

Mild 1 reports 5.9%

Increased Hunger (Hunger Noise)

Mild 1 reports 5.9%

Mild Depression

Mild 1 reports 5.9%

Risks & Warnings

Important safety considerations based on clinical data and community reports.

!

Psychiatric Effects

3 mentions

Monitor for mood changes. Report any concerning psychiatric symptoms to healthcare provider.

i

Water Retention

15 mentions

Fluid retention can occur with GH-releasing peptides. Usually mild and temporary.

i

Injection Site Reactions

14 mentions

Local reactions are common and usually mild. Rotate injection sites.

Dosing

Standard Protocol

Starting Dose: 100mcg 1-3x daily (no DAC) or 2mg weekly (with DAC)
Titration: No established protocol
Half-life: ~30 min (no DAC) or ~8 days (with DAC)
Administration: Subcutaneous injection

Community Dosing Patterns

Based on 76 mentions

Community-reported patterns, not medical advice.

250mcg daily

8

daily

6

200mcg daily

6

5x/week

2

125mcg daily

2

Pricing

Research-grade reference pricing for 5mg vial. Prices vary by vendor and quantity. Research chemicals require self-mixing and lack medical oversight. Shipping is not included.

We do not list vendors. Prices are aggregated from community reports and should be treated as rough ranges.

US Research Grade

$35.5

Single small vial from US domestic vendors

US Research (Bulk)

$28.03

Per-dose equivalent when buying larger US vials

China Research

$9.25

Per-vial when buying 10-pack from Chinese vendors

Research

3

Total Articles

1

Clinical Trials

1

Reviews

Key Studies

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Review

J Am Acad Orthop Surg Glob Res Rev (2026)

Probing for peptidic drugs (2-10 kDa) in doping control blood samples Preclinical

Anal Sci Adv (2022)

Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS Preclinical

Anal Bioanal Chem (2016)

Commonly Stacked With

From community members' documented stacks involving CJC-1295.

Ipamorelin 193 stacks (97.5%)

Retatrutide 66 stacks (33.3%)

Tirzepatide 36 stacks (18.2%)

Tesamorelin 25 stacks (12.6%)

BPC-157 23 stacks (11.6%)

Switching Patterns

Based on 49 discussions about switching to or from CJC-1295.

→ Switching FROM

Retatrutide 8 mentions

Ipamorelin 8 mentions

Tesamorelin 5 mentions

Tirzepatide 3 mentions

Users who switched to CJC-1295

← Switching TO

Retatrutide 9 mentions

Ipamorelin 6 mentions

BPC-157 5 mentions

TB-500 3 mentions

Users who switched from CJC-1295